PIHN Announces Procannas’ Cannabinoid Transdermal Product Development

Polaris International Holdings, Inc. (PIHN) is excited to announce its medical division, ProCannas, has begun development of a unique and proprietary transdermal patch capable of delivering cannabinoids directly through the skin. This hallmark solution is intended to address a significant, unmet need for individuals requiring long-term, time released delivery. The Company believes, subject to testing and trials to be initiated by our participating physicians, that the patch may able to deliver cannabinoids for up to 48 hours. The Company further expects that this mechanism of delivery could revolutionize the way cannabinoids are introduced into the blood stream minimizing the negative effects on lungs and other organs commonly seen in other delivery methods. The Company expects to be ready to begin trials in 90 days.

The Company intends to target a broad range of specialties with this novel product, including but not limited to sports medicine, pain management, neurology, and osteopathic medicine.

“Transdermal delivery of Cannabinoids has a global reach because diseases such as osteoporosis which affects about 52 million Americans and causes more than 8.9 million fractures worldwide annually, resulting in an osteoporotic fracture every 3 seconds, will greatly benefit from this method of delivery. It will ensure long term absorption on a continual basis in order to alleviate the targeted symptoms. Constant delivery of cannabinoids transdermally will also help to reduce pain and swelling in other medical conditions,” states Medical Director, Dr. Vasthi Alvarez Avila.

ABOUT THE COMPANY

ProCannas core business focuses on the manufacture and distribution of new, pharmaceutical grade cannabinoid based products for medicinal use. Due to the concentrated strength and unique mix of ingredients integrated within our products, they are intended to be available to patients only through licensed participating physicians. Due to recent changes in the law regarding the medical use of marijuana, coupled with studies and a strong body of evidence highlighting that THC is not the significant component for medicinal use, doors are opening for innovation. Laws are expected to become even more favorable for companies like ProCannas.

Advertisements

Tags: , , , , ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: